



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

November 18, 2020

Christian Schade  
Chairman and Chief Executive Officer  
Aprea Therapeutics, Inc.  
535 Boylston Street  
Boston, MA 02116

**Re: Aprea Therapeutics, Inc.**  
**Registration Statement on Form S-3**  
**Filed November 12, 2020**  
**File No. 333-250041**

Dear Mr. Schade:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jason L. Drory at 202-551-8342 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Istvan A. Hajdu, Esq.